The partners will use UNP's AI-based macrocycle discovery platform to develop synthetic peptide therapeutics for multiple ...

Spokane may be hundreds of miles from major academic medical centers, but its becoming a national leader in an advanced ...

Boehringer Ingelheim Pharma GmbH & Co KG has selected a third oncology drug candidate to advance into IND-enabling studies under its ongoing collaboration with Oxford Biotherapeutics Ltd.

Cancer-hunting antibodies coupled with a natural compound found in soil microbes proved a powerful combination against an aggressive type of blood cancer, according to a new study from scientists at ...

During therapy, some cancer cells evolve to escape elimination. Newer anticancer drugs that can overcome this resistance are ...

Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

The acquired Seagen products contributed meaningfully to Pfizer’s revenues in 2024 and in the first quarter of 2025. Seagen also has some next-generation ADC candidates in its pipeline.

The addition of Seagen in 2023 also strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. The acquired Seagen products contributed meaningfully to ...

Sakar Healthcare jumped 4.65% to Rs 344.20 after the company announced the receipt of second marketing authorization (MA) of oncology injection (product registration) for the European Union (EU). The ...

DNA-encoded chemical library (DECL) screens are a rapid and economical tool to identify chemical starting points for drug discovery. As a robust transformation for drug discovery, palladium-catalyzed ...